Preclinical Development
CIRM's Preclinical Development grant funds preclinical research on stem cell and genetic therapies to support FDA IND clearance and enable clinical trial startup.
Funder: California Institute for Regenerative Medicine
Due Dates: September 24, 2026 (Consultation request deadline) | October 8, 2026 (Application deadline)
Funding Amounts: Up to $13 million per award; maximum duration 5 years; co-funding required for for-profit applicants.
Summary: Supports preclinical development of stem cell-based or genetic therapies to achieve FDA IND clearance and clinical trial startup.
Key Information: Consultation with CIRM is required before application; only California organizations are eligible.
Description
This opportunity supports the preclinical development of stem cell-based or genetic therapy candidates, with the goal of advancing projects to FDA Investigational New Drug (IND) clearance and clinical trial startup. The program is designed to accelerate transformative therapies for diseases affecting Californians, emphasizing both scientific innovation and patient access. CIRM acts as a funding partner and provides expert guidance to help awardees overcome key translational barriers, with a strong focus on data sharing and collaborative knowledge exchange.
